Ra Capital Management, L.P. Purchases 1,833,000 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) Director Ra Capital Management, L.P. acquired 1,833,000 shares of the company’s stock in a transaction on Monday, September 16th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $32,994,000.00. Following the acquisition, the director now owns 4,303,418 shares of the company’s stock, valued at approximately $77,461,524. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Bicara Therapeutics Price Performance

Shares of NASDAQ BCAX traded down $1.34 during trading hours on Wednesday, reaching $25.73. The stock had a trading volume of 299,459 shares, compared to its average volume of 502,486. Bicara Therapeutics Inc. has a fifty-two week low of $21.05 and a fifty-two week high of $27.94.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.